{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:54:44Z","timestamp":1790834084008,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejps.2020.105426","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T16:09:10Z","timestamp":1592064550000},"page":"105426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Improving the dissolution of a water-insoluble orphan drug through a fused deposition modelling 3-Dimensional printing technology approach"],"prefix":"10.1016","volume":"152","author":[{"given":"Mehtap","family":"SAYDAM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"TAKKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105426_bib0020","unstructured":"Affinisol HPMC HME for Hot Melt Extrusion, 2020. Dow Pharma."},{"key":"10.1016\/j.ejps.2020.105426_bib0001","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s11095-016-1933-1","article-title":"Emergence of 3D Printed Dosage Forms: opportunities and Challenges","volume":"33","author":"Alhnan","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105426_bib0002","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2010.03.014","article-title":"Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions","volume":"391","author":"Ali","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.molliq.2018.07.065","article-title":"Solubilization of drugs using sodium lauryl sulfate: experimental data and modeling, J","volume":"268","author":"Alizadeh","year":"2018","journal-title":"Mol. Liq."},{"key":"10.1016\/j.ejps.2020.105426_bib0004","first-page":"501","article-title":"New stability indicating liquid chromatographic method for the quantitative determination of Rufinamide in presence of degredant products","volume":"4","author":"Annapurna","year":"2012","journal-title":"Drug Invent. Today"},{"key":"10.1016\/j.ejps.2020.105426_bib0005","unstructured":"ApreciaPharmaceuticals, Aprecia, 2017. http:\/\/www.pharmtech.com\/aprecia-pharmaceuticals-and-cycle-pharmaceuticals-partner-develop-3d-printed-orphan-drugs."},{"key":"10.1016\/j.ejps.2020.105426_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejps.2018.03.019","article-title":"Tablet fragmentation without a disintegrant: a novel design approach for accelerating disintegration and drug release from 3D printed cellulosic tablets","volume":"118","author":"Arafat","year":"2018","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2020.105426_bib0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5505\/epilepsi.2012.63935","article-title":"A Case of Lennox-Gastaut Syndrome Who Developed Tonic Status Epilepticus Induced by Intravenous Diazepam","volume":"18","author":"Atmaca","year":"2012","journal-title":"J. Turkish Epilepsi Soc."},{"key":"10.1016\/j.ejps.2020.105426_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.18433\/jpps30347","article-title":"Understanding the role of sodium lauryl sulfate on the biorelevant solubility of a combination of poorly water-soluble drugs using high throughput experimentation and mechanistic absorption modeling","volume":"22","author":"Bahr","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0011","article-title":"Hot-Melt Extrusion with BASF Pharma Polymers","year":"2012","journal-title":"Extrusion Compendium"},{"key":"10.1016\/j.ejps.2020.105426_bib0009","unstructured":"BASF, 2019. Soluplus\u00ae Technical Information."},{"key":"10.1016\/j.ejps.2020.105426_bib0012","unstructured":"Bauer L., Supporting rare disease drug development: CDER's rare diseases program, 2017. https:\/\/www.fda.gov\/media\/104959\/download."},{"key":"10.1016\/j.ejps.2020.105426_bib0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijpharm.2014.12.032","article-title":"Ink-jet printing versus solvent casting to prepare oral films: effect on mechanical properties and physical stability","volume":"494","author":"Buanz","year":"2015","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.ejps.2020.105426_bib0016","first-page":"2156","article-title":"Dissolution rate enhancement of an anti-convulsant drug","volume":"5","author":"Chatakonda","year":"2012","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105426_bib0017","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/js960105t","article-title":"Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate","volume":"86","author":"Crison","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0018","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1590\/S1984-82502013000400026","article-title":"Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification","volume":"49","author":"Dezani","year":"2013","journal-title":"Brazilian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0019","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1211\/jpp.59.5.0004","article-title":"Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method","volume":"59","author":"Douroumis","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105426_bib0022","first-page":"1","article-title":"Inovelon Film-coated tablets summary of product characteristics","year":"2019","journal-title":"Electron. Med. Compend"},{"key":"10.1016\/j.ejps.2020.105426_bib0026","unstructured":"European Medicines Agency (EMA), Inovelon Assessment report, EMA\/18473\/2017. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/inovelon-h-c-660-ii-37-epar-assessment-report_en.pdf (2017)."},{"key":"10.1016\/j.ejps.2020.105426_bib0029","unstructured":"Evaluate Pharma, Orphan Drug Report , (2017) 1\u201326."},{"key":"10.1016\/j.ejps.2020.105426_bib0032","unstructured":"FDA, Office of orphan products development. https:\/\/www.fda.gov\/about-fda\/office-special-medical-programs\/office-orphan-products-development (2020)."},{"key":"10.1016\/j.ejps.2020.105426_bib0033","unstructured":"Food and drug Administration (FDA), Banzel\u00ae (rufinamide) film-coated tablet Prescribing information. 2020. https:\/\/www.banzel.com\/~\/media\/Files\/BanzelPatient\/BanzelPI.pdf."},{"key":"10.1016\/j.ejps.2020.105426_bib0024","unstructured":"Food and Drug Administration (FDA) Rufinamide orphan drug designation. 2004."},{"key":"10.1016\/j.ejps.2020.105426_bib0073","unstructured":"Food and drug Administration (FDA) Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules (2015)."},{"key":"10.1016\/j.ejps.2020.105426_bib0031","unstructured":"Food and Drug Administration (FDA) Dissolution methods. 2020."},{"key":"10.1016\/j.ejps.2020.105426_bib0035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.powtec.2016.06.032","article-title":"A physically stabilized amorphous solid dispersion of nisoldipine obtained by hot melt extrusion","volume":"301","author":"Fu","year":"2016","journal-title":"Powder Technol"},{"key":"10.1016\/j.ejps.2020.105426_bib0036","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2014.12.012","article-title":"Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats","volume":"68","author":"G\u00e1ll","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0037","unstructured":"Gattefosse, From lead to investigational new drug, guide for successful preclinical studies with Gattefosse excipients, 2000, in Gattefosse."},{"key":"10.1016\/j.ejps.2020.105426_bib0038","unstructured":"Gattefosse, Lipid based formulations for oral bioavailability enhancement formulation guidlines: oral lipid-based formulations, 2015, in Gattefosse."},{"key":"10.1016\/j.ejps.2020.105426_bib0039","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2655-y","article-title":"An Effective Technology for the Development of Immediate Release Solid Dosage Forms Containing Low-Dose Drug: fused Deposition Modeling 3D Printing","volume":"36","author":"G\u00fcltekin","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105426_bib0040","first-page":"20","article-title":"Combining HME & solubilization: soluplus\u00ae - The solid solution, Drug Deliv","volume":"10","author":"Hardung","year":"2010","journal-title":"Technol"},{"key":"10.1016\/j.ejps.2020.105426_bib0014","unstructured":"HME Cleaner Plus (GMP) Product Information, 2001. Biogrund."},{"key":"10.1016\/j.ejps.2020.105426_bib0013","unstructured":"HME Cleaner Plus (GMP) Specification, 2000. Biogrund."},{"key":"10.1016\/j.ejps.2020.105426_bib0027","unstructured":"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview. 2020."},{"key":"10.1016\/j.ejps.2020.105426_bib0030","unstructured":"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/size-shape-and-other-physical-attributes-generic-tablets-and-capsules. 2015."},{"key":"10.1016\/j.ejps.2020.105426_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijpharm.2019.04.017","article-title":"3D printed oral theophylline doses with innovative \u2018radiator-like\u2019 design: Impact of polyethylene oxide (PEO) molecular weight","volume":"564","author":"Isreb","year":"2019","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejps.2020.105426_bib0041","unstructured":"Jacob, J., Coyle, N., West, T.G., Monkhouse, D.C., Surprenant, H.L., Jain, N.B. US 9.339.489 B2 Rapid disperse dosage form containing levetiracetam, 2016."},{"key":"10.1016\/j.ejps.2020.105426_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/pt050345","article-title":"Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note","volume":"5","author":"Jain","year":"2004","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2020.105426_bib0043","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijpharm.2015.09.009","article-title":"Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity","volume":"495","author":"Jannin","year":"2015","journal-title":"Int. J. Pharm"},{"key":"10.1016\/j.ejps.2020.105426_bib0044","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2018.01.024","article-title":"3D extrusion printing of high drug loading immediate release paracetamol tablets","volume":"538","author":"Khaled","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0045","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.braindev.2018.07.020","article-title":"Rufinamide efficacy and safety in children aged 1\u20134 years with Lennox\u2013Gastaut syndrome","volume":"40","author":"Kim","year":"2018","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejps.2020.105426_bib0046","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jps.22290","article-title":"Degradation of polysorbates 20 and 80: Studies on thermal autoxidation and hydrolysis","volume":"100","author":"Kishore","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0047","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1021\/acs.chemrev.7b00074","article-title":"Polymers for 3D Printing and Customized Additive Manufacturing","volume":"117","author":"Ligon","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2020.105426_bib0048","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1208\/s12249-013-9971-z","article-title":"Plasticizer Effects on Physical\u2013Mechanical Properties of Solvent Cast Soluplus\u00ae Films","volume":"14","author":"Lim","year":"2013","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejps.2020.105426_bib0049","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00216-011-5126-9","article-title":"Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva","volume":"401","author":"Mazzucchelli","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejps.2020.105426_bib0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11208630-000000000-00000","article-title":"Rufinamide- A Pharmacoeconomic Profile of its Use as Adjunctive Therapy in Lennox-Gastaut Syndrome","volume":"30","author":"McCormack","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejps.2020.105426_bib0051","doi-asserted-by":"crossref","first-page":"191","DOI":"10.15415\/jptrm.2013.12012","article-title":"Analytical Method Development and Validation for Assay of Rufinamide Drug","volume":"1","author":"Mehta","year":"2013","journal-title":"J. Pharm. Technol. Res. Manag."},{"key":"10.1016\/j.ejps.2020.105426_bib0053","unstructured":"Portmann R., HofmeierU.C. , Burkhard A. , Scherrer W. , Szelagiewicz M. , US 6740669B1: Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide and its use as antiepileptic, 2004."},{"key":"10.1016\/j.ejps.2020.105426_bib0054","first-page":"33","article-title":"Preparation and characterization of rufinamide HP-\u03b2-cyclodextrin complexes prepared by the kneading method for solubility enhancement","volume":"54","author":"Ravish","year":"2013","journal-title":"Ars Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijpharm.2017.10.056","article-title":"Melt extrusion with poorly soluble drugs-an integrated review","volume":"535","author":"Repka","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0056","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1081\/DDC-100102218","article-title":"Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot melt extrusion","volume":"25","author":"Repka","year":"1999","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jconrel.2017.11.022","article-title":"Channelled tablets: An innovative approach to accelerating drug release from 3D printed tablets","volume":"269","author":"Sadia","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.ejps.2020.105426_bib0057","first-page":"231","article-title":"Bioavailability File:rufinamide","volume":"44","author":"Saydam","year":"2019","journal-title":"FABAD J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0058","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.xphs.2016.08.027","article-title":"Theoretical analysis of drug dissolution in micellar media","volume":"106","author":"Shekunov","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0059","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.xphs.2017.10.021","article-title":"Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling (FDM): screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability","volume":"107","author":"Solanki","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10847-017-0710-z","article-title":"Cyclodextrin complexation improves aqueous solubility of the antiepileptic drug, rufinamide: solution and solid state characterization of compound-cyclodextrin binary systems","volume":"88","author":"Szabo","year":"2017","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.ejps.2020.105426_bib0028","unstructured":"The International Council for Harmonisation (ICH), 1995. Q2 (R1) Validation of analytical procedures. (ICH)."},{"key":"10.1016\/j.ejps.2020.105426_bib0061","unstructured":"USP 40, 2017. \u30081087\u3009; Apparent intrinsic dissolution: dissolution testing procedures for rotating disk and stationary disk, in. USP 40."},{"key":"10.1016\/j.ejps.2020.105426_bib0063","unstructured":"USP 40, 2017. \u30081092\u3009; The Dissolution Procedure: development and Validation., in. USP 40."},{"key":"10.1016\/j.ejps.2020.105426_bib0062","unstructured":"USP 40, 2017. Rufinamide Tablets monograph. USP 40, 6084\u20136086."},{"key":"10.1016\/j.ejps.2020.105426_bib0064","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.xphs.2018.09.019","article-title":"Development of solid dispersion by hot melt extrusion using mixtures of polyoxylglycerides with polymers as carriers for increasing dissolution rate of a poorly soluble drug model","volume":"108","author":"Vasoya","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105426_bib0065","first-page":"44","article-title":"Measurement of intrinsic drug dissolution rates using two types of apparatus","author":"Viegas","year":"2001","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejps.2020.105426_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2639-y","article-title":"A Proof of Concept for 3D Printing of Solid Lipid-Based Formulations of Poorly Water-Soluble Drugs to Control Formulation Dispersion Kinetics","volume":"36","author":"Vithani","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105426_bib0067","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ejpb.2013.09.007","article-title":"Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs","volume":"85","author":"Vo","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0068","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13318-015-0291-4","article-title":"Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects","volume":"41","author":"Xu","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2020.105426_bib0069","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2011.10.053","article-title":"Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes","volume":"422","author":"Yan","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2020.105426_bib0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2003.10.016","article-title":"Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs","volume":"270","author":"Yu","year":"2004","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720302153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:53:33Z","timestamp":1760529213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720302153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":67,"alternative-id":["S0928098720302153"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105426","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the dissolution of a water-insoluble orphan drug through a fused deposition modelling 3-Dimensional printing technology approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105426"}}